Platinum-resistant Ovarian Cancer Completed Phase 2 Trials for Zilovertamab vedotin (DB18457)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04504916A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)Treatment